EA015580B1 - Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты - Google Patents

Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты Download PDF

Info

Publication number
EA015580B1
EA015580B1 EA200870234A EA200870234A EA015580B1 EA 015580 B1 EA015580 B1 EA 015580B1 EA 200870234 A EA200870234 A EA 200870234A EA 200870234 A EA200870234 A EA 200870234A EA 015580 B1 EA015580 B1 EA 015580B1
Authority
EA
Eurasian Patent Office
Prior art keywords
met
antibody
sec
cells
spk
Prior art date
Application number
EA200870234A
Other languages
English (en)
Russian (ru)
Other versions
EA200870234A1 (ru
Inventor
Паоло Мария Комольо
Элиза Винья
Силвия Джордано
Original Assignee
Метерезис Транслейшнл Ресерч С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метерезис Транслейшнл Ресерч С.А. filed Critical Метерезис Транслейшнл Ресерч С.А.
Publication of EA200870234A1 publication Critical patent/EA200870234A1/ru
Publication of EA015580B1 publication Critical patent/EA015580B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200870234A 2006-02-06 2007-02-05 Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты EA015580B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (2)

Publication Number Publication Date
EA200870234A1 EA200870234A1 (ru) 2009-02-27
EA015580B1 true EA015580B1 (ru) 2011-10-31

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870234A EA015580B1 (ru) 2006-02-06 2007-02-05 Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты

Country Status (21)

Country Link
US (2) US8388958B2 (enExample)
EP (2) EP1981981B1 (enExample)
JP (1) JP5306828B2 (enExample)
KR (1) KR101429297B1 (enExample)
CN (1) CN101379192B (enExample)
AT (1) ATE514715T1 (enExample)
AU (1) AU2007213804B2 (enExample)
BR (1) BRPI0707480A8 (enExample)
CA (1) CA2638889C (enExample)
CY (1) CY1111884T1 (enExample)
DK (1) DK1981981T3 (enExample)
EA (1) EA015580B1 (enExample)
ES (1) ES2368864T3 (enExample)
IL (1) IL192879A (enExample)
MX (1) MX2008009833A (enExample)
PL (1) PL1981981T3 (enExample)
PT (1) PT1981981E (enExample)
SG (2) SG169382A1 (enExample)
SI (1) SI1981981T1 (enExample)
WO (1) WO2007090807A1 (enExample)
ZA (1) ZA200806559B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
ES2993335T3 (en) 2010-03-10 2024-12-27 Genmab As Monoclonal antibodies against c-met
WO2011125458A1 (ja) * 2010-04-02 2011-10-13 富士レビオ株式会社 抗癌剤の効果の診断用マーカー
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
RU2013114783A (ru) * 2010-09-03 2014-10-10 Академиа Синика Anti-с-мет антитела и способы их применения
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
EP2500036B1 (en) * 2011-03-18 2014-05-07 Metheresis Translational Research SA MET inhibitors for enhancing radiotherapy efficacy
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
TW201326193A (zh) 2011-11-21 2013-07-01 Genentech Inc 抗－ｃ－ｍｅｔ抗體之純化
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
EP2863946A4 (en) * 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
KR102443619B1 (ko) * 2016-09-29 2022-09-14 미쓰비시 타나베 파마 코퍼레이션 cMET 단일클론 결합제, 이의 약물 접합체 및 이의 용도
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
MX2020010110A (es) 2018-03-28 2020-11-06 Mitsubishi Tanabe Pharma Corp Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
AU2024282613A1 (en) 2023-06-01 2025-11-20 Pierre Fabre Medicament Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AMENDOLA MARIO ET AL.: "Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters" NATURE BIOTECHNOLOGY, vol. 23, no. 1, January 2005 (2005-01), pages 108-116, XP002389318 ISSN: 1087-0156 pages 108-110 *
BALYASNIKOVA IRINA V. ET AL.: "Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface" BIOCHEMICAL JOURNAL, vol. 362, no. 3, 15 March 2002 (2002-03-15), pages 585-595, XP002389317 ISSN: 0264-6021 the whole document *
BARDELLI ET AL.: "Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 334, no. 4, 9 September 2005 (2005-09-09), pages 1172-1179, XP005001511 ISSN: 0006-291X figure 2 *
CORTESINA G. ET AL.: "Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 MAY 2000, vol. 89, no. 3, 20 May 2000 (2000-05-20), pages 286-292, XP002430067 ISSN: 0020-7136 page 286 - page 288 figure 2 *
GALVANI ARTURO P. ET AL.: "Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form" BIOCHEMICAL PHARMACOLOGY, vol. 50, no. 7, 1995, pages 959-966, XP002389315 ISSN: 0006-2952 figure 1 *
HAY RICK V. ET AL.: "Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek)." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OST 2005, vol. 11, no. 19 Pt 2, 1 October 2005 (2005-10-01), pages 7064s-7069s, XP002430068 ISSN: 1078-0432 figures 1-4 *
MICHIELI PAOLO ET AL.: "Targeting the tumor and its microenvironment by a dual-function decoy Met receptor" CANCER CELL, vol. 6, no. 1, July 2004 (2004-07), pages 61-73, XP002389313 ISSN: 1535-6108 cited in the application the whole document *
PETRELLI A. ET AL.: "Ab-induced ectodomain shedding mediates hepatocytes growth factor receptor down-regulation and hampers biological activity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 28 MAR 2006 UNITED STATES, vol. 103, no. 13, 28 March 2006 (2006-03-28), pages 5090-5095, XP002389316 ISSN: 0027-8424 page 5095, column 1, lines 12-14 *
PRAT M. ET AL.: "AGONISTIC MONOCLONAL ANTIBODIES AGAINST THE MET RECEPTOR DISSECT THE BIOLOGICAL RESPONSES TO HGF" JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 111, no. PART 2, 1998, pages 237-247, XP000943567 ISSN: 0021-9533 cited in the application page 243 - page 244 pages 240-244 figure 8 *
WAJIH NADEEM ET AL.: "Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met)" CIRCULATION RESEARCH, vol. 90, no. 1, 11 January 2002 (2002-01-11), pages 46-52, XP002389314 ISSN: 0009-7330 figures 4,6 *

Also Published As

Publication number Publication date
SI1981981T1 (sl) 2012-01-31
KR20090013745A (ko) 2009-02-05
BRPI0707480A2 (pt) 2011-05-03
US20120134996A1 (en) 2012-05-31
US8388958B2 (en) 2013-03-05
ZA200806559B (en) 2012-12-27
KR101429297B1 (ko) 2014-08-12
CN101379192A (zh) 2009-03-04
SG169383A1 (en) 2011-03-30
ES2368864T3 (es) 2011-11-23
CA2638889A1 (en) 2007-08-16
EP1981981B1 (en) 2011-06-29
AU2007213804B2 (en) 2012-12-13
SG169382A1 (en) 2011-03-30
US8729043B2 (en) 2014-05-20
EP2192188A1 (en) 2010-06-02
IL192879A (en) 2014-02-27
JP2009526010A (ja) 2009-07-16
CN101379192B (zh) 2013-07-31
PT1981981E (pt) 2011-10-04
MX2008009833A (es) 2008-10-23
AU2007213804A1 (en) 2007-08-16
IL192879A0 (en) 2009-02-11
AU2007213804A8 (en) 2008-08-28
DK1981981T3 (da) 2011-09-26
CA2638889C (en) 2015-06-02
EP1981981A1 (en) 2008-10-22
CY1111884T1 (el) 2015-11-04
PL1981981T3 (pl) 2011-11-30
JP5306828B2 (ja) 2013-10-02
BRPI0707480A8 (pt) 2022-11-08
ATE514715T1 (de) 2011-07-15
EA200870234A1 (ru) 2009-02-27
WO2007090807A1 (en) 2007-08-16
US20090285807A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
EA015580B1 (ru) Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты
Valencia et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis
JP5572718B2 (ja) 乳癌を処置するための方法
Yang et al. Semaphorin 4D promotes skeletal metastasis in breast cancer
US6767541B2 (en) HER-2/neu overexpression abrogates growth inhibitory pathways
JP2005530687A (ja) Ｆｇｆｒアゴニスト
US20100111964A1 (en) Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
US20090123462A1 (en) Fgfr agonists
US20060234271A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
Zhang et al. A novel signaling pathway: fibroblast nicotinic receptor α1 binds urokinase and promotes renal fibrosis
US20080020461A1 (en) Kinesin-like proteins and methods of use
US20210379147A1 (en) Method and system for treating cancer utilizing tinagl1
US9383364B2 (en) Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
KR100877824B1 (ko) Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CN113773368A (zh) 一种foxm1拮抗多肽及其衍生物与应用
Jakowlew Transforming growth factor-β in lung cancer, carcinogenesis, and metastasis
KR20190040585A (ko) Human Stm1 (hStm1) 유전자의 발현 또는 hSTM1 단백질의 활성을 억제하는 물질을 포함하는, 위암의 예방 또는 치료용 약학적 조성물
Ha Distinct ShcA Signaling Complexes Influence Breast Tumor Growth and Resistance to Tyrosine Kinase Inhibitors
Eccles Models for evaluation of targeted therapies of invasive and metastatic disease
Mullins The role of the Fer protein-tyrosine kinase in HER2-positive breast cancer
McCarthy A role for TRPV6 ion channels in prostate cancer bone metastases
JP2000279194A (ja) 抗癌剤のスクリーニング方法
KR20080071950A (ko) Ｐｕｍａ의 암 침윤 또는 전이 표적으로서의 용도

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM